4.8 Article

Immune Regulation by Pericytes: Modulating Innate and Adaptive Immunity

Journal

FRONTIERS IN IMMUNOLOGY
Volume 7, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2016.00480

Keywords

pericytes; innate immunity; inflammation; adaptive immunity; tumor microenvironment

Categories

Funding

  1. Institute de Sapid Carlos III [PI13/00090]
  2. European Regional Development FEDER funds
  3. Comunidad de Madrid [S2010-BMD-2312]
  4. Ministerio de Economia y Competitividad [BIO2011-22738]

Ask authors/readers for more resources

Pericytes (PC) are mural cells that surround endothelial cells in small blood vessels. PC have traditionally been credited with structural functions, being essential for vessel maturation and stabilization. However, an accumulating body of evidence suggests that PC also display immune properties. They can respond to a series of pro -inflammatory stimuli and are able to sense different types of danger due to their expression of functional pattern-recognition receptors, contributing to the onset of innate immune responses. In this context, PC not only secrete a variety of chemokines but also overexpress adhesion molecules such as ICAM-1 and VCAM-1 involved in the control of immune cell trafficking across vessel walls. In addition to their role in innate immunity, PC are involved in adaptive immunity. It has been reported that interaction with PC anergizes T cells, which is attributed, at least in part, to the expression of PD-L1. As components of the tumor microenvironment, PC can also modulate the antitumor immune response. However, their role is complex, and further studies will be required to better understand the crosstalk of PC with immune cells in order to consider them as potential therapeutic targets. In any case, PC will be looked at with new eyes by immunologists from now on.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Antonio Tapia-Galisteo, Inigo Sanchez Rodriguez, Oscar Aguilar-Sopena, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocio Navarro, Laura Martin-Garcia, Cesareo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Alvarez-Vallina, Laura Sanz

Summary: In this study, a novel trispecific T-cell recruiting antibody was developed for the treatment of colorectal cancer, which showed improved efficacy and enhanced tumor selectivity.

ONCOIMMUNOLOGY (2022)

Article Oncology

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

Belen Blanco, Angel Ramirez-Fernandez, Clara Bueno, Lidia Argemi-Muntadas, Patricia Fuentes, Oscar Aguilar-Sopena, Francisco Gutierrez-Aguera, Samanta Romina Zanetti, Antonio Tapia-Galisteo, Laura Diez-Alonso, Alejandro Segura-Tudela, Maria Castella, Berta Marzal, Sergi Betriu, Seandean L. Harwood, Marta Compte, Simon Lykkemark, Ainhoa Erce-Llamazares, Laura Rubio-Perez, Anais Jimenez-Reinoso, Carmen Dominguez-Alonso, Maria Neves, Pablo Morales, Estela Paz-Artal, Sonia Guedan, Laura Sanz, Maria L. Toribio, Pedro Roda-Navarro, Manel Juan, Pablo Menendez, Luis Alvarez-Vallina

Summary: This study compares the efficacy of CAR-T19 cells and STAb-T19 cells and finds that STAb-T19 cells are more effective in inducing cytotoxicity, avoiding leukemia escape, and preventing relapse. CAR-T19 cells induce leukemia escape through rapid CD19 internalization and degradation, while STAb-T19 cells prevent CD19 downmodulation by forming canonical immunologic synapses. In a long-term patient-derived xenograft mouse model, STAb-T19 cells efficiently eradicate leukemia cells, while leukemia relapse occurs after CAR-T19 therapy.

CANCER IMMUNOLOGY RESEARCH (2022)

Article Multidisciplinary Sciences

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity

Oana Hangiu, Marta Compte, Anders Dinesen, Rocio Navarro, Antonio Tapia-Galisteo, Ole A. Mandrup, Ainhoa Erce-Llamazares, Rodrigo Lazaro-Gorines, Daniel Nehme-Alvarez, Carmen Dominguez-Alonso, Seandean L. Harwood, Carlos Alfonso, Belen Blanco, Laura Rubio-Perez, Anais Jimenez-Reinoso, Laura Diez-Alonso, Francisco J. Blanco, Laura Sanz, Kenneth A. Howard, Luis Alvarez-Vallina

Summary: This study introduces bispecific antibodies fused with human and mouse sequences that specifically target the tumor microenvironment to provide 4-1BB costimulation. These antibodies show specific targeting of the tumor cells and provide costimulatory activity, with prolonged circulatory half-life and tumor inhibition effects. Combining these antibodies with PD-1-blocking antibodies enhances the therapeutic effect.

ISCIENCE (2022)

Review Medicine, Research & Experimental

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy

Antonio Tapia-Galisteo, Marta Compte, Luis alvarez-Vallina, Laura Sanz

Summary: Multispecific antibodies have the potential to overcome current limitations and have important implications in cancer therapy.

THERANOSTICS (2023)

Article Medicine, Research & Experimental

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, Nicolas Bouquin, Stephanie Cornen, Francis Duffieux, Pierre Ferre, Raphaelle Gillet, Christian Jorgensen, Mark B. Leick, Bernard Maillere, Helene Negre, Mireia Pelegrin, Nicolas Poirier, Dietmar Reusch, Bruno Robert, Guy Serre, Alain Vicari, Martin Villalba, Christoph Volpers, Gavin Vuddamalay, Herve Watier, Thierry Wurch, Lennart Zabeau, Stefan Zielonka, Baolin Zhang, Alain Beck, Pierre Martineau

Summary: The annual Antibody Industrial Symposium brought together scientists from academia and industry to discuss new advancements in antibody engineering and cell-based therapies. The symposium also addressed production and intellectual property protection issues.
Article Oncology

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Laura Rubio-Perez, Rodrigo Lazaro-Gorines, Seandean L. Harwood, Marta Compte, Rocio Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belen Blanco, Simon Lykkemark, Angel Ramirez-Fernandez, Mariola Ferreras-Gutierrez, Carmen Dominguez-Alonso, Laura Diez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J. Blanco, Cruz Santos, Jose L. Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina

Summary: In this study, a PD-L1/EGFR symmetric bispecific antibody was developed, which could simultaneously inhibit EGFR-mediated proliferation, effectively block PD-1/PD-L1 interaction, and induce strong antigen-specific antibody-dependent cellular cytotoxicity activity in vitro. Potent therapeutic efficacies of this antibody were observed in two different humanized mouse models.

ONCOIMMUNOLOGY (2023)

Review Oncology

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies

Antonio Tapia-Galisteo, Luis alvarez-Vallina, Laura Sanz

Summary: Immune cell engagers are modified antibodies that have one arm binding a tumor-associated antigen and another arm binding an activating receptor in immune effector cells. These engagers have the potential to revolutionize the treatment of hematological malignancies and are more potent than conventional monoclonal antibodies. The field is growing rapidly, with multiple formats and targets currently in clinical trials, and trispecific antibodies show even more promise by targeting additional tumor-associated antigens or costimulatory receptors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Article Chemistry, Multidisciplinary

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

Rodrigo Lazaro-Gorines, Patricia Perez, Ignacio Heras-Murillo, Irene Adan-Barrientos, Guillermo Albericio, David Astorgano, Sara Flores, Joanna Luczkowiak, Nuria Labiod, Seandean L. Harwood, Alejandro Segura-Tudela, Laura Rubio-Perez, Yudhi Nugraha, Xiaoran Shang, Yuxing Li, Carlos Alfonso, Kaylin A. Adipietro, Dinendra L. Abeyawardhane, Rocio Navarro, Marta Compte, Wenbo Yu, Alexander D. Mackerell, Laura Sanz, David J. Weber, Francisco J. Blanco, Mariano Esteban, Edwin Pozharski, Raquel Godoy-Ruiz, Ines G. Munoz, Rafael Delgado, David Sancho, Juan Garcia-Arriaza, Luis Alvarez-Vallina

Summary: In this study, a broadly neutralizing antibody (nAb) TNT was generated, which showed high-avidity neutralizing interaction by simultaneously binding to all six RBD epitopes. By fusing an anti-DNGR-1 scFv to TNT, a bispecific trimerbody TN(T)DNGR-1 was generated, which targeted neutralized virions to cDC1s and promoted T cell cross-priming. Therapeutic administration of TN(T)DNGR-1 protected mice from lethal SARS-CoV-2 infection and enhanced virus-specific humoral and CD8(+) T cell responses.

ADVANCED SCIENCE (2023)

Article Biochemistry & Molecular Biology

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment

Javier Narbona, Luisa Hernandez-Baraza, Ruben G. Gordo, Laura Sanz, Javier Lacadena

Summary: Immunotoxins are chimeric molecules that combine the specificity of an antibody-based targeting domain and the cytotoxic potency of a toxin. This study designed and characterized several immunotoxin constructs using nanobodies as targeting domains against EGFR. The results confirm the therapeutic potential of a-sarcin-based nanoITXs.

BIOMOLECULES (2023)

No Data Available